Caption Management, LLC Immunovant, Inc. Call Options Transaction History

Caption Management, LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$27.51 - $27.51 $4.65 Million - $4.65 Million	169,200 Added 135.36%	294,200 $8.09 Million
Q2 2024 Aug 14, 2024	SELL	$25.1 - $31.61 $2.32 Million - $2.92 Million	-92,500 Reduced 42.53%	125,000 $3.3 Million
Q1 2024 May 15, 2024	SELL	$30.27 - $43.79 $2.06 Million - $2.98 Million	-68,000 Reduced 23.82%	217,500 $7.03 Million
Q4 2023 Feb 14, 2024	SELL	$31.31 - $44.19 $13.4 Million - $18.8 Million	-426,500 Reduced 59.9%	285,500 $12 Million
Q3 2023 Nov 14, 2023	BUY	$18.55 - $39.96 $12.9 Million - $27.8 Million	694,500 Added 3968.57%	712,000 $27.3 Million
Q1 2023 May 15, 2023	BUY	$15.27 - $19.72 $267,225 - $345,100	17,500 New	17,500 $271,000
Q4 2021 Feb 11, 2022	SELL	$7.33 - $9.32 $1.36 Million - $1.73 Million	-185,200 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$9.4 - $16.85 $227,480 - $407,770	-24,200 Reduced 11.56%	185,200 $1.96 Million
Q1 2021 May 17, 2021	BUY	$13.08 - $49.6 $2.74 Million - $10.4 Million	209,400 New	209,400 $3.36 Million

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.